drugset
drugset / Trial / NCT06685341

PK/PD Study of YZJ-1139

NCT06685341 ↗

Phase 1 Completed 20 enrolled Shanghai Haiyan Pharmaceutical Technology Co., Ltd.
RandomizedCrossoverDouble-blindTreatment

Summary

Primary Objective： To determine the dose-response relationship of YZJ-1139 in young and elderly Chinese subjects after a single oral administration of different doses, and to compare it with zolpidem at clinical doses. Secondary Objective: To investigate the safety and tolerability of YZJ-1139 in young and elderly Chinese subjects after a single oral administration of different doses, and to compare it with zolpidem at clinical doses.

Timeline

Start
2019-03-07
Primary completion
2019-04-10
Completion
2019-11-15

Drugs

EvaluationDrugModalityDoseRoute
Subject FAZAMOREXANT Small molecule — Oral
Comparator Zolpidem Small molecule — Oral

Indications

insomnia